Key Takeaways
- H1 revenue up 30%, guidance held: Consolidated revenue grew 25% Y-o-Y in Q2 and 30% in H1, and management reaffirmed the FY27 target of 30–40% top-line growth with 50–60% PAT growth.
- Margins leapt despite dormant subsidiaries: EBITDA margin improved 290 bps Y-o-Y in Q2 and ~530 bps in H1, even as Zoraya and Amerisyn operating costs hit the P&L with zero revenue contribution yet.
- The launch pipeline is now the story: 41 approved but unlaunched ANDAs, 43 more in the pipeline, 944 emerging-market registrations awaiting approval, and two subsidiaries about to go live make the next 6–8 quarters a commercialization race.
- Branded generics flipped from volume to value: Gross margin on India branded generics swung from 18–20% last year to over 60% this year on similar scale, a deliberate portfolio shift that changes the earnings quality of the segment.
- What to watch next quarter: Whether Amerisyn and Zoraya actually commence commercialization within the promised 10–45 day window, the pace of ANDA approvals against the 3–4 new ANDA and 12–15 sANDA target for Q3, and whether emerging-market margins rebound to the mid-to-late teens as October trends suggest.
The Commercialization Backlog
The quarter’s defining feature was not what shipped but what sits approved and unlaunched. The company holds 41 approved ANDAs yet to be commercialized, plus 43 pipeline ANDAs, for a total of 84 products to roll out over the next 2–4 years. In emerging markets, 944 filed registrations await approval, expected to convert over the next 2–4 quarters. Management cautioned that the pace cannot be modeled as a simple quarterly division because regulatory processes, quota applications, and distributor sell-in cycles sit outside its control.
- Why Q2 was quiet on new ANDA launches: The one ANDA approval received was for a controlled substance, which triggers a 45–50 day post-approval sequence of quota application, API ordering, manufacturing, and shipping; launch is now expected by November end.
- sANDA launches filled the gap: Three sANDAs covering four strengths were commercialized, with two strengths as first-to-launch in the US on a molecule with over $1 billion in market size; the remaining two are second-to-launch, small-niche but highly profitable products.
- Unbilled revenue spiked for a reason: Two or three large products were launched and shipped in September, so accrued income rose because distributors will begin selling only in the current quarter.
- CDMO/CMO stayed at ~35% of regulated-market revenue: The own-product portfolio accelerated faster than the CDMO/CMO segment, though three ANDAs covering 12 strengths were commercialized for CDMO/CMO partners during the quarter.
Sanjay Majmudar: "And it can't happen at, you know, divide by the number of quarters. It has to be looked at on a more broader time frame of maybe 6 to 12 months, because many things are not under our control."
Subsidiary Activation: Amerisyn & Zoraya
Two acquisitions are incurring operating costs inside the P&L with no revenue offset, making their activation the single largest near-term margin and growth lever. Both are expected to go live imminently, and management stated that once revenues begin, existing operating costs will be easily absorbed, and they do not expect any margin dip, but will continue to monitor how margins progress.
- Amerisyn: Over 20 state registrations have been received, and commercialization is expected to begin within 10–15 days of the October 29 call; more than 10 products are planned for launch within the next two quarters.
- Zoraya: Commercialization is expected within the current quarter, with a worst-case timeline of about 45 days from the call date; 14 ANDAs are planned for launch under Zoraya as Zoraya becomes live.
- Margin direction is up but unquantified: Management confirmed the direction is toward improvement once the subsidiaries operationalize, but declined to pinpoint timing or magnitude, saying only that margins should stabilize or improve slightly as revenues come in.
Swapnil Shah: "Difficult to pinpoint. I mean, the direction is there as you stated. But till both the subsidiaries are operationalized to a level that we would like it to be, commenting whether the margin will further strengthen beyond what they are today will be a little tough."
Apnar Facility: Full Machines, Half Revenue
The Apnar injectables facility is running at 90–100% capacity, but more than half of that capacity is consumed by validation work for future product launches rather than revenue-generating production. Revenue of approximately INR21 crores in Q2 came largely from the five ANDAs acquired with the facility.
- Capacity build-out underway: A third commercial line is being installed, and a fourth is planned before March 31, 2027, targeting total production capacity of about 120 crore units across four lines.
- Revenue inflection expected from November/December: New product filings from Apnar are expected to begin commercializing from November or December onward, with the facility still on track to contribute about INR100-odd crores of revenue this year.
- FDA inspection cleared with minor findings: The facility successfully concluded an FDA inspection, receiving one minor procedural 483; European PIC/S approval was also received in H1, strengthening regulatory credentials for emerging-market registrations.
Swapnil Shah: "So, it's almost at peak, I would say, that the utilization is there. But the complete utilization is not generating in the revenue as yet. Since there's lot of validation work, more than 50% validation work is going on."
Emerging Markets: Margin Volatility Masks Structural Shift
Emerging-market revenue grew ~21% in Q2 and 25% in H1, and the business has turned cash positive. But Q2 margins dipped because of a product-mix swing: there were few large orders of beta-lactam products, which are relatively high-price antibiotics in a competitive landscape. Management urged investors to view the segment on a longer horizon, and October trends already point to a rebound toward the mid-to-late teens.
- H1 margins were ~10%, Q2 was lower: Per an analyst's math, Q2 emerging-market margins were approximately 4%, but management stated H1 margins stood at about 10% and October is already trending toward the mid-to-late teens guidance, with November and December looking promising.
- Full-year expectation held at mid-to-lower teens: The next two quarters are expected in the mid-teens to later teens, pulling the full-year figure to the guided range.
- Branded generics transformation is the hidden story: India branded generics gross margin swung from 18–20% last year to over 60% this year on similar scale, reflecting a deliberate shift from a volume-focused to a margin-focused business; the segment is expected to reach INR50–60 crores this year.
Sanjay Majmudar: "See, quarterly run rate is very difficult to maintain because the business does not happen the way we want actually. So, I think you should look at us on a little longer horizon as Swapnil said. It should be maintained. Don't worry about it."
Regulated Markets: First-to-Launch Products Lift Realizations
Regulated-market revenue grew 28% Y-o-Y in Q2 and 34% in H1, with the ANDA portfolio nearly doubling from 34 to 64. Sequential EBITDA margin improvement was driven primarily by new launches with good realization, especially first-to-launch products in the US, which carry structurally higher margins.
- Controlled substances are the next margin driver: Four to five controlled-substance launches are expected before March 31, 2027, in categories with limited competition and some complex specialty products; the first of these launches is scheduled for November end.
- Margin direction is upward: Management stated regulated-market margins should either stay at current levels or improve by 1–2 percentage points going forward, driven by new launches, and explicitly said margins are not expected to go down.
- Quarter-to-quarter variation is inherent: Product mix drives volatility, so management advised viewing margins on a year-to-year basis rather than sequentially.
Swapnil Shah: "Do we expect it to go down? The answer is no, if that is the question you'll be asking."
Pipeline Breadth Beyond ANDAs
The company is building growth levers that extend beyond the core ANDA portfolio, with several initiatives approaching revenue inflection in H2 FY27 and beyond.
- GLP-1 and peptide portfolio: Commercialization is in process across 18–20 emerging markets including the Middle East, Africa, Latin America, Far East, and CIS; the portfolio includes semaglutide and the full peptide range, with drug substance and drug product manufactured in-house and pre-filled syringe devices outsourced.
- New product launches at Aavis and Havix: Both subsidiaries have products slated for H2 commercialization.
- Ratnatris contribution: Expected to be much stronger in H2 in terms of bottom line than H1.
- Technology investments: The company has invested heavily in AI-backed applications across functions and digitized operations with SAP HANA, though no quantified productivity or cost benefits were disclosed.
- India critical care field force: Significant expansion of field force and market reach has been completed, strengthening the foundation for the domestic branded business.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 revenue growth | 30% to 40% Y-o-Y | FY27 full year |
| FY27 PAT growth | 50% to 60% Y-o-Y | FY27 full year |
| FY27 EBITDA margin | 30% plus, definitely not 28% | FY27 full year |
| Amerisyn commercialization start | Within 10–15 days from Oct 29, 2026 | Mid-November 2026 |
| Zoraya commercialization start | Within current quarter; worst case ~45 days from Oct 29, 2026 | By mid-December 2026 |
| Amerisyn product launches | More than 10 products | Next two quarters |
| Zoraya ANDA launches | 14 ANDAs | FY27 |
| Controlled substance ANDA launch | First product launch by November end | Q3 FY27 |
| Controlled substance launches | 4–5 products | Before March 31, 2027 |
| Q3 ANDA approvals | 3–4 new ANDAs and 12–15 sANDAs | Q3 FY27 |
| Apnar commercial lines | 4 lines, ~120 crore units capacity | By March 31, 2027 |
| Apnar revenue contribution | ~INR100-odd crores plus | FY27 |
| Apnar new product commercialization | Filings begin commercializing | November/December 2026 onward |
| Emerging markets full-year margin | Mid-teens to lower teens | FY27 |
| Emerging markets near-term margin | Mid-teens to later teens | Next two quarters |
| Branded generics revenue | INR50–60 crores with >60% gross margin | FY27 |
| Approved ANDA commercialization | 41 approved but unlaunched ANDAs | Next 6–8 quarters |
| Total ANDA commercialization | 84 ANDAs (41 approved + 43 pipeline) | Next 2–4 years |
| Emerging market registration approvals | 944 filed registrations | Next 2–4 quarters |
| Beyond-FY27 revenue growth | ~25% annual growth | Next 2–3 years |
| Bottom-line vs top-line growth | PAT growth to exceed revenue growth | FY27 |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹192 cr, +25% YoY, highest-ever quarterly revenue |
| EBITDA | ₹58 cr, +38% YoY |
| EBITDA margin | 30%, +290 bps YoY; operating EBITDA, reported EBITDA higher due to other income |
| PAT | ₹36.6 cr, +22% YoY |
| H1 FY27 revenue | ₹372.5 cr, +30% YoY |
| H1 FY27 EBITDA | ₹111 cr, +58% YoY |
| H1 FY27 EBITDA margin | ~30%, +530 bps YoY |
| H1 FY27 PAT | ₹67 cr, +31% YoY |
| FY27 revenue growth guidance | 30% to 40%, maintained |
| FY27 PAT growth guidance | 50% to 60%, maintained |
| Beyond FY27 annual growth guidance | ~25% over next 2 to 3 years |
| Regulated market revenue growth | +28% YoY in Q2, +34% in H1 FY27 |
| Emerging market revenue growth | ~21% YoY in Q2, +25% in H1 FY27 |
| Approved ANDAs | 64 as of Sep 2026, up from 34 in Sep 2025; 23 commercialized |
| ANDAs commercialized in Q2 | 3 sANDAs (4 strengths), 3 CDMO ANDAs (12 strengths); 1 new ANDA approved, launch in Q3 |
| CDMO CMO share of regulated market revenue | ~35% |
| Apnar facility revenue | ₹21 cr in Q2; on track for ₹100 cr+ in FY27 |
| Apnar capacity utilization | 90% to 100%, with over 50% on validation work |
| Emerging markets H1 FY27 EBITDA margin | ~10%; full-year expected mid to lower teens |
| Branded generics India gross margin | >60% in FY27, up from 18% to 20% last year on similar scale |
| Zoraya and Amerisyn pre-revenue costs in Q2 | ~₹4 cr, recognized in P&L with no corresponding revenue |
| Operating cash flow | ₹38 cr in H1 FY27 |
| Capex | ~₹46 cr in H1 FY27 |
| Emerging markets registrations | 558 approved, 944 filed awaiting approval |
| Zoraya planned ANDA launches in FY27 | 14 |